Advaxis Highlights Presentation Of Updated Data From Ongoing Phase 1/2 Trial Of ADXS-503 In Non-Small Cell Lung Carcinoma At American Society Of Clinical Oncology: 'show disease control rate of 44% with durable clinical benefit observed beyond one year'